📣 Creators, Exciting News!
Gate Square Certified Creator Application Is Now Live!
How to apply:
1️⃣ Open App → Tap [Square] at the bottom → Click your avatar in the top right
2️⃣ Tap [Get Certified] under your avatar
3️⃣ Once approved, you’ll get an exclusive verified badge that highlights your credibility and expertise!
Note: You need to update App to version 7.25.0 or above to apply.
The application channel is now open to KOLs, project teams, media, and business partners!
Super low threshold, just 500 followers + active posting to apply!
At Gate Square, everyone can be a community leader! �
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a “buy” rating.